OMNIAB INC (OABI) Stock Price & Overview

NASDAQ:OABIUS68218J1034

Current stock price

1.54 USD
-0.02 (-1.28%)
At close:
1.54 USD
0 (0%)
After Hours:

The current stock price of OABI is 1.54 USD. Today OABI is down by -1.28%. In the past month the price decreased by -23%. In the past year, price decreased by -26.32%.

OABI Key Statistics

52-Week Range1.22 - 2.295
Current OABI stock price positioned within its 52-week range.
1-Month Range1.47 - 2.035
Current OABI stock price positioned within its 1-month range.
Market Cap
222.961M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.57
Dividend Yield
N/A

OABI Stock Performance

Today
-1.28%
1 Week
-2.53%
1 Month
-23.00%
3 Months
-18.09%
Longer-term
6 Months -5.52%
1 Year -26.32%
2 Years -65.32%
3 Years -55.75%
5 Years N/A
10 Years N/A

OABI Stock Chart

OMNIAB INC / OABI Daily stock chart

OABI Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to OABI. When comparing the yearly performance of all stocks, OABI is a bad performer in the overall market: 86.46% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

OABI Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to OABI. While OABI has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

OABI Earnings

On March 4, 2026 OABI reported an EPS of -0.11 and a revenue of 8.38M. The company missed EPS expectations (-21.76% surprise) and missed revenue expectations (-8.79% surprise).

Next Earnings DateMay 6, 2026
Last Earnings DateMar 4, 2026
PeriodQ4 / 2025
EPS Reported-$0.11
Revenue Reported8.376M
EPS Surprise -21.76%
Revenue Surprise -8.79%

OABI Forecast & Estimates

13 analysts have analysed OABI and the average price target is 7.48 USD. This implies a price increase of 385.71% is expected in the next year compared to the current price of 1.54.

For the next year, analysts expect an EPS growth of 29.32% and a revenue growth 44.88% for OABI


Analysts
Analysts84.62
Price Target7.48 (385.71%)
EPS Next Y29.32%
Revenue Next Year44.88%

OABI Groups

Sector & Classification

OABI Financial Highlights

Over the last trailing twelve months OABI reported a non-GAAP Earnings per Share(EPS) of -0.57. The EPS increased by 5% compared to the year before.


Income Statements
Revenue(TTM)18.67M
Net Income(TTM)-64.78M
Industry RankSector Rank
PM (TTM) N/A
ROA -21.53%
ROE -24.26%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%8.33%
Sales Q2Q%-22.47%
EPS 1Y (TTM)5%
Revenue 1Y (TTM)-29.27%

OABI Ownership

Ownership
Inst Owners40.73%
Shares144.78M
Float106.83M
Ins Owners6.77%
Short Float %5.28%
Short Ratio15.96

About OABI

Company Profile

OABI logo image OmniAb, Inc. operates as a drug discovery company. The company is headquartered in Emeryville, California and currently employs 89 full-time employees. The company went IPO on 2020-10-09. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets.

Company Info

IPO: 2020-10-09

OMNIAB INC

5980 Horton Street, Suite 600

Emeryville CALIFORNIA US

Employees: 89

OABI Company Website

OABI Investor Relations

Phone: 15102507800

OMNIAB INC / OABI FAQ

What does OMNIAB INC do?

OmniAb, Inc. operates as a drug discovery company. The company is headquartered in Emeryville, California and currently employs 89 full-time employees. The company went IPO on 2020-10-09. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets.


What is the stock price of OMNIAB INC today?

The current stock price of OABI is 1.54 USD. The price decreased by -1.28% in the last trading session.


What is the dividend status of OMNIAB INC?

OABI does not pay a dividend.


How is the ChartMill rating for OMNIAB INC?

OABI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What do analysts say about OMNIAB INC (OABI) stock?

13 analysts have analysed OABI and the average price target is 7.48 USD. This implies a price increase of 385.71% is expected in the next year compared to the current price of 1.54.


Can you provide the market cap for OMNIAB INC?

OMNIAB INC (OABI) has a market capitalization of 222.96M USD. This makes OABI a Micro Cap stock.